Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer
21 Avril 2020 - 1:17PM
Business Wire
Dr. Golan, an infectious disease thought leader
at Tufts Medical Center, fills key clinical position to help
advance Appili’s infectious disease portfolio
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or
“Appili”), a biopharmaceutical company focused on anti-infective
drug development, today announced that it has appointed Yoav Golan,
MD, to serve as the Company’s first Chief Medical Officer (CMO).
Dr. Golan has spent his more than 25 year-career as an infectious
disease (ID) medical specialist, most recently serving as an
attending physician in the Division of Geographic Medicine and
Infectious Diseases at Tufts Medical Center, and as an associate
professor at Tufts University School of Medicine in Boston. In his
role as Appili’s CMO, Dr. Golan will be responsible for the
clinical development strategy and execution across all of Appili’s
pipeline assets, which is comprised of a broad spectrum of
antimicrobial candidates. In particular, he will be a leadership
resource for applying medical and scientific rigor to Appili’s
clinical programs.
“As Appili’s pipeline assets progress toward active clinical
trials, and our focus expands to include multiple types of
antimicrobial programs, now is the optimal time to add
patient-centered medical expertise to our leadership team,” said
Armand Balboni, MD, PhD, Chief Executive Officer, Appili
Therapeutics. “We are thrilled to have an executive with Yoav’s
caliber to lead our clinical programs; his lifelong commitment to
patients and the breadth and depth of his infectious disease acumen
will be invaluable resources for our work.”
Dr. Golan has conducted extensive research in the ID space,
publishing several books and over 50 peer-reviewed studies in
journals including The New England Journal of Medicine and The
Lancet Infectious Diseases. His research focuses on
hospital-acquired infections with emphasis on ICU infections, the
impact of antibiotic resistance on outcomes, and development of
early culture-independent treatment strategies. Dr. Golan’s recent
work has focused on C. difficile infections as well as invasive
candidiasis. He has been involved in the development of multiple
anti-infectives, including, fidaxomicin, ceftaroline and
bezlotuximab.
In addition to his work at Tufts, he has served several
executive positions at biotechnology companies, including as Chief
Scientific Officer of Profility Inc. and as Chief Executive
Officer, ExArca Pharmaceuticals. He is on the peer review committee
of multiple medical and scientific journals and is a member of
numerous medical societies, including the Infectious Disease
Society of America and the American Society for Microbiology. Dr.
Golan is a graduate of the Hadassah School of Medicine at the
Hebrew University in Jerusalem, Israel. He completed a medicine
residency and Infectious Diseases fellowship at the Tel Aviv
Sourasky Medical Center, followed by a transplant ID fellowship and
masters in statistics and modeling at Tufts University School of
Medicine.
“Now more than ever, we need strong, creative, and viable
solutions to address the increasing threat of emerging infections,”
said Dr. Golan. “Appili is doing excellent work to advance critical
programs in the infectious disease space, and I look forward to
continued work with the Board and the Company’s leadership team to
advance research and help the patients who need better
anti-infective options.”
Dr. Golan has served Appili in an advisory capacity since the
Company’s inception in 2016. He will initially join Appili’s
leadership team in a part time role and plans to maintain his work
with Tufts Medical Center, also in a part-time capacity.
About Appili Therapeutics Appili Therapeutics Inc. was
founded to advance the global fight against infectious disease by
matching clearly defined patient needs with drug development
programs that provide solutions to existing challenges patients,
doctors, and society face in this critical disease space. Appili
has built a pipeline of assets designed to address a broad range of
significant unmet medical needs in the infectious disease
landscape. This diverse pipeline aims to address some of the most
urgent threats in global public health, including ATI-2307, a
novel, broad spectrum, clinical-stage antifungal candidate in
development for severe and difficult-to-treat invasive fungal
infections; ATI-1701, a vaccine candidate for tularemia, a very
serious biological weapons threat; ATI-1503, a drug discovery
program aimed at generating a novel class of antibiotics with
broad-spectrum activity against Gram-negative superbugs; and
ATI-1501, which employs Appili’s proprietary, taste-masked,
oral-suspension technology with metronidazole for the growing
number of patients with difficulty swallowing. Headquartered in
Halifax, Nova Scotia, with offices in Toronto, Ontario, Appili is
pursuing worldwide opportunities in collaboration with scientific
and industry commercial partners, governments and government
agencies. For more information, visit
www.AppiliTherapeutics.com.
Forward looking statements This news release contains
“forward-looking statements” which reflect the current expectations
of the Company’s management for future growth, results of
operations, performance and business prospects and opportunities.
Wherever possible, words such as “may “, “would “, “could “,
“should”, “will,” “anticipate,” “believe,” “plan,” “expect,”
“intend,” “estimate,” “potential for” and similar expressions have
been used to identify these forward-looking statements.
Forward-looking statements involve significant known and unknown
risks, uncertainties and assumptions, including, without
limitation, those listed in the annual information form of the
Company dated July 3, 2019 and the other filings made by the
Company with the Canadian securities’ regulatory authorities (which
may be viewed at www.sedar.com). Should one or more of these risks
or uncertainties materialize or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
Neither the TSX Venture Exchange, nor its regulation services
provider (as that term is defined in the policies of the exchange),
accepts responsibility for the adequacy or accuracy of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005117/en/
Media Relations Contact: Andrea Cohen Sam Brown Inc. T:
917-209-7163 E: andreacohen@sambrown.com
Investor Relations Contact: Kimberly Stephens, CFO Appili
Therapeutics Inc. TSXV: APLI E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSXV:APLI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Appili Therapeutics (TSXV:APLI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024